Related Experiment Videos
Two cases of nabumetone induced pseudoporphyria
1Department of Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA.
The Journal of Rheumatology
|December 22, 1999
Summary
Nabumetone, a nonsteroidal anti-inflammatory drug, can cause pseudoporphyria. Physicians should be aware of this rare side effect when prescribing nabumetone to patients.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Drug-induced pseudoporphyria is a rare condition that mimics porphyria cutanea tarda.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently implicated in its development.
Observation:
- Two new cases of pseudoporphyria associated with nabumetone (Relafen) are presented.
- These cases add to the limited existing reports linking nabumetone to this adverse drug reaction.
Findings:
- Nabumetone is confirmed as a potential causative agent for pseudoporphyria.
- The clinical presentation in the reported cases aligns with established features of drug-induced pseudoporphyria.
Implications:
- Increased physician awareness of nabumetone-induced pseudoporphyria is crucial for early diagnosis and management.
- This finding highlights the need for careful patient monitoring when prescribing NSAIDs, particularly nabumetone.